Short-course radiation versus long-course chemoradiation for rectal cancer: Making progress

Journal of Clinical Oncology

Volumn 30, Issue 31, 2012, Pages 3777-3778

  Minsky, Bruce D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; EDITORIAL; FOLLOW UP; HUMAN; LONG TERM CARE; MORBIDITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RECTUM CANCER; RECURRENCE RISK; TREATMENT DURATION; TREATMENT OUTCOME;

ADENOCARCINOMA; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS;

EID: 84869233601     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.0551     Document Type: Editorial

References (13)

1. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer: Swedish Rectal Cancer Trial. N Engl J Med 336:980-987, 1997
2. Birgisson H, Påahlman L, Gunnarsson U, et al: Adverse effects of preoperative radiation therapy for rectal cancer: Long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23:8697-8705, 2005 (Pubitemid 46211513)
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646, 2001
4. van Gijn W, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575-582, 2011
5. Sauer R, Becker H, Hohenberger P, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740, 2004
6. Sauer R, Liersch T, Merkel S, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926-1933, 2012
7. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215-1223, 2006 (Pubitemid 44547018)
8. Bujko K, Bujko M: Point: Short-course radiation therapy is preferable in the neoadjuvant treatment of rectal cancer. Semin Radiat Oncol 21:220-227, 2011
9. Ngan SY, Burmeister B, Fisher RJ, et al: Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol 30:3827-3833, 2012
10. Peeters KC, Marijnen CA, Nagtegaal ID, et al: The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693-701, 2007 (Pubitemid 350035641)
11. Pettersson D, Cedermark B, Holm T, et al: Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 97:580-587, 2010
12. van Dijk TH, Havenga K, Beukema J, et al: Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer: A phase II multicenter study of the Dutch Colorectal Cancer Group. J Clin Oncol 28:295s, 2010 (suppl 15; abstr 3638)
13. Myerson RJ, Parikh PJ, Tan B, et al: A single institution phase II trial of five fractions of radiotherapy followed by four courses of FOLFOX chemotherapy as preoperative therapy for rectal adenocarcinoma. J Clin Oncol 30, 2012 (suppl 4; abstr 553)